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Abstract
Biomedical scientists are aggressively investigating biomarkers of
disease and injury. The rationale for identifying biomarkers during
pathological states, such as severe sepsis, is to improve clinical
prognostication and stratify therapeutic interventions for optimal
recovery. An added benefit of biomarker studies is knowledge
genesis on pathophysiological mechanisms, critical information
that provides a basis for hypothesis-driven research. Unfortunately,
biomarkers rarely alter our clinical approach in severe sepsis as
they are often non-specific, lack adequate sensitivity and/or are
difficult to measure and interpret accurately. Given the complexity
and heterogeneity of severe sepsis, and the unique genetically
derived susceptibilities of individuals, it is highly unlikely that one or
even a handful of biomarkers will provide adequate biomedical
information for clinical guidance. Thus, biomarkers will ultimately
alter clinical decision making only once a panel of promising
biomarkers is identified, maximizing sensitivity and specificity, and
then adequately scrutinized with quantitative scoring methods over
large populations of patients.
Severe sepsis is a leading cause of morbidity and mortality.
Despite increased understanding of its pathophysiology, our
ability to prognosticate in individual patients with severe
sepsis is poor. Thus, there are ongoing investigations to
discover novel biomarkers to complement our clinical ability
to predict disease evolution and stratify therapies. Gäddnäs
and colleagues [1] report in a recent issue of Critical Care
that the utilization of collagen metabolism biomarker levels
retrospectively exhibited correlation with disease severity and
differentiated between survivors and non-survivors in a cohort
of patients with severe sepsis. The authors postulate that the
products of collagen metabolism may have a role as
biomarkers in severe sepsis, but is measurement of these
collagen-related biomarkers likely to provide meaningful
clinical guidance?
Collagens comprise approximately 30% of the body’s protein
content and provide much of the structural strength and
elasticity of human tissue [2]. Type I and III collagen fibers are
derived from procollagen precursor molecules from which
amino-terminal propeptides are cleaved to generate the
amino-terminal propeptides of type I procollagen (PINP) and
type III procollagen (PIIINP). Type I collagen is widely
distributed and PINP has been utilized as an index of type I
collagen synthesis in tissues. Type III collagen is found in
skin, blood vessel walls and hollow viscera. PIIINP is most
commonly utilized as a marker of type III collagen synthesis in
early wound repair, but increased concentrations of PIIINP
have also been described in various disease states. The
carboxy-terminal telopeptide of type I collagen (ICTP) is a
product of type I collagen elimination. As nicely demonstrated
by Gäddnäs and colleagues [1], PINP, PIIINP and ICTP were
all elevated in patients with severe sepsis, indicating
significant collagen metabolism, with PINP and PIIINP levels
correlating with disease severity.
While intriguing, the results of this severe sepsis biomarker
study by Gäddnäs and colleagues [1] are likely contaminated
by co-morbidities and administered therapies. For example,
increased PIIINP levels have been measured in the serum of
patients with hepatic cirrhosis and acute respiratory distress
syndrome, and in the bronchoalveolar lavage fluid of patients
with sarcoidosis and fibrosing alveolitis. Of more direct
relevance, ischaemic heart disease, chronic heart failure,
diabetes and chronic obstructive airway disease (which
represented the co-morbidities in 61% of the patients with
severe sepsis [1]) are also associated with altered collagen
metabolism. Furthermore, therapies such as norepinephrine
(which was administered to 86% of the severe sepsis
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patients [1]) produce increases in type I and III collagen
within the extracellular matrix of the heart [3]. Given these
confounding influences, there is some difficulty in teasing out
the effect of severe sepsis per se, a problem exacerbated by
a limited sample population. The investigators appropriately
recognize that matching of chronic disease states would
enhance the study [1], but this omission might be of more
significance than a simple study design weakness.
Fibrosis is an end stage process consisting primarily of
collagen deposition [4]. Extracellular matrix remodeling is,
however, dynamic, altering in character as the disease process
develops. Collagen metabolism is largely regulated by
proteases, particularly a class of enzymes referred to as the
matrix metalloproteinases (MMPs) and their endogenous
tissue inhibitors (TIMPs) [5]. MMPs and TIMPs not only
regulate collagen turnover, but are also the effectors for the
action of a number of interleukins and growth factors, and
may represent a more appropriate measure of the state of
tissue remodeling in severe sepsis than collagen-related
factors. For example, a recent study reported elevated levels
of MMP-9, TIMP-2 and TIMP-1 in severe sepsis [6], with
TIMP-1 identified as having some potential to serve as a
useful biomarker in predicting the clinical outcome of patients
with severe sepsis.
An intriguing observation reported by Gäddnäs and
colleagues [1] is the persistence of increased levels of PIIINP
and PINP, suggesting that severe sepsis continues to cause
metabolic disequilibrium long after clinical recovery. Severe
sepsis might initiate a sustained inflammatory response,
associated with ongoing collagen metabolism, thereby
underlying the poor long-term outcome in adult survivors [7].
While an in-hospital mortality of 51% was reported in 153
adults with sepsis, the post-hospital discharge mortality at 6
months and 1 year was 68% and 79%, respectively [7]. The
continued evidence of disordered collagen metabolism [1],
presumably in the absence of treatment effects, may render
the byproducts of collagen production more useful bio-
markers of a chronic dysfunction rather than acute phase
reactants. Indeed, evidence demonstrates that disordered
collagen metabolism results in significant disruption of tissue
structure and function due either to collagen loss or
excessive deposition.
An ideal severe sepsis biomarker must be specifically linked
to the disease itself and to a therapeutic decision, not only its
differential expression in severe sepsis patients or even its
association with adverse outcome [8]. Collagen metabolism
biomarkers are plausible prognostic agents, as reported by
Gäddnäs and colleagues [1], but only in the context of a
larger panel of biomarkers [9]. Other promising severe sepsis
biomarkers, which might eventually be combined with
collagen-related markers, include IL-6, IL-8, IL-10, C-reactive
protein, procalcitonin, MMP-9 and TIMP-1 [6,10-13]. Once
an ideal panel of biomarkers is determined, relatively rapid
biomarker assays using multiplex [14] and antibody micro-
array [15] technology may be widely available in the near
future and yield critical severe sepsis prognostic information
in the form of a patient-specific biomarker profile.
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